Scabies notes on pg levels make into eassay

Reading File

Finding Sources

Reading File

I now have comprehensive, detailed scabies content from multiple authoritative textbooks. I have enough to write a thorough PG-level essay. Let me compose it now.

Scabies: A Comprehensive Review

Introduction

Scabies is a highly contagious, intensely pruritic infestation of the skin caused by Sarcoptes scabiei var. hominis, an obligate human ectoparasite. Known colloquially as the "seven-year itch," this condition has plagued humanity for over 2,500 years and remains a global public health burden to this day. In 2017, the World Health Organization designated scabies a neglected tropical disease, acknowledging the need for coordinated international control strategies. An estimated 150-200 million individuals are affected globally at any given time, with an overall worldwide prevalence of approximately 2.5%. - Dermatology 2-Volume Set 5e, p. 1812

Epidemiology

Scabies affects all ages, races, and socioeconomic groups without discrimination. However, its prevalence is disproportionately higher in resource-limited settings, with rates in low-income countries ranging from 4% to 70%. Environmental and social factors that facilitate its spread include overcrowding, institutional settings (nursing homes, prisons, military barracks), delayed diagnosis, and poor public awareness. Incidence is higher in tropical regions and tends to surge during natural disasters, armed conflicts, economic crises, and refugee displacement.

Among special populations, prevalence is elevated in children, sexually active individuals, and the elderly. In developed countries, scabies most commonly presents in epidemic or institutional outbreaks. In some Australian Aboriginal communities, household dogs have been identified as potential reservoirs for human-adapted scabies mites. - Dermatology 2-Volume Set 5e, Harrison's Principles of Internal Medicine 22E

Etiology and Parasitology

The causative agent is Sarcoptes scabiei var. hominis, a member of class Arachnida, family Sarcoptidae. The mite is pearl-like, translucent, white, oval, and eyeless, possessing four pairs of short stubby legs. The adult female measures approximately 0.35-0.4 × 0.3 mm, rendering it just too small to be seen with the naked eye; the male is slightly smaller. Critically, Sarcoptes mites that infest other animals (e.g., S. scabiei var. canis in dogs) are not adapted to reside or reproduce in humans - they may cause transient bite reactions but do not establish true infestation. - Fitzpatrick's Dermatology, p. 3304

The entire 30-day life cycle is completed within the human epidermis. The fertilized female excavates a sloping burrow through the stratum corneum to the boundary of the stratum granulosum, advancing at 0.5-5 mm per day by a combination of chewing and body motions. Along this path - which can reach 1 cm in length - she deposits 2-4 eggs per day, laying up to 50 eggs during her 30-day lifespan. Eggs hatch within 10-12 days, releasing larvae that migrate to the skin surface to mature. After molting, larvae become nymphs, which can only survive 2-5 days off a host. Male mites live on the skin surface and enter burrows solely to mate. - Fitzpatrick's Dermatology

An important practical point: the mite can survive for 3 days off a human host in ambient conditions, and even longer (up to 7 days) in mineral oil. This limited but real off-host survival time is the basis for fomite transmission and the importance of environmental decontamination. - Fitzpatrick's Dermatology

Pathogenesis and Immunology

In a first-time infestation, the host typically harbors only 10-15 (range 3-50) adult female mites. An infested individual does not develop symptoms immediately; the incubation period before pruritus develops ranges from 4 to 6 weeks (or up to 3 months), reflecting the time required for the host to mount a type IV delayed hypersensitivity response to mite proteins, feces (scybala), and eggs. Upon re-infestation, prior sensitization means symptoms appear within 2-3 days. Some individuals never become sensitized and remain entirely asymptomatic carriers - an epidemiologically critical phenomenon. - Fitzpatrick's Dermatology

Histologically, there is a patchy to diffuse dermal infiltrate rich in eosinophils, along with lymphocytes and histiocytes. A transected mite may occasionally be visualized within the epidermis. Pink "pigtail"-like fragments of adult mite exoskeleton in the stratum corneum serve as a diagnostic clue when intact mites, eggs, and fecal pellets are absent. The eosinophil-rich infiltrate is driven by IgE-mediated responses to scabietic antigens. Research into PCR-based detection and serologic testing (IgE specific for recombinant S. scabiei antigens) is ongoing. - Dermatology 2-Volume Set 5e

Clinical Features

Classic Scabies

The hallmark symptom is intense, nocturnal pruritus - characteristically worse at night and after hot showers. The primary pathognomonic lesion is the burrow: a dark, wavy, thread-like line in the superficial epidermis, 3-15 mm in length, representing the female mite's tunnel. Burrows are most reliably found in the interdigital web spaces, volar aspects of the wrists, lateral palms, and along the sides of the fingers. However, burrows are often difficult to identify because they are obscured by excoriations or secondary impetiginization.

The full distribution of lesions in classic scabies encompasses:

Interdigital web spaces (fingers and toes)
Volar wrists and lateral palms
Elbows and axillae
Periumbilical skin and belt line
Genitalia - particularly the penile glans, shaft, and scrotum in males (near-universal involvement)
Female areolae and labia
Buttocks and upper thighs

In healthy adults, the face, scalp, neck, palms, and soles are almost invariably spared. In infants and young children, involvement is generalized - including the face, scalp, palms, and soles - and the predominant lesions are papules and vesicopustules rather than classic burrows. In infants, indurated crusted nodules are also seen in intertriginous areas and on the trunk. - Harrison's Principles 22E; Fitzpatrick's Dermatology; Rosen's Emergency Medicine

Scabietic Nodules

Persistent reddish-brown nodules, particularly on the scrotum and buttocks, represent a hypersensitivity reaction to retained mite antigens. These nodular lesions may persist for weeks to months after successful eradication of the mite.

Crusted (Norwegian) Scabies

Crusted scabies is a severe variant of the infestation defined by hyperkeratotic, thick, yellowish-white scaly plaques and dystrophic nails, most prominently affecting the palmar and plantar surfaces. It closely mimics psoriasis in appearance. The critical distinction is that it results from an immunological failure to control mite burden - affected individuals may harbor thousands to millions of mites on their skin surface, rendering them extraordinarily contagious. Even casual proximity to a patient with crusted scabies can transmit the infestation; concentrations of 6,000 mites per gram of debris have been detected in floor dust and bedding from affected individuals' rooms.

Populations at risk for crusted scabies include:

Elderly individuals (impaired immune senescence, reduced scratching response)
HIV/AIDS patients and other immunocompromised states (solid organ transplant recipients, patients on chronic immunosuppressants or glucocorticoids)
HTLV-1-infected individuals
Neurologic conditions that blunt itch perception or impair the scratch response (leprosy, paraplegia, dementia)
Psychiatric disorders

Paradoxically, pruritus is often minimal or absent in crusted scabies, as the sensory or immune pathways that normally drive the itch response are disrupted. Characteristic burrows are also not seen. Hospital outbreaks of common scabies have repeatedly been traced to a single undiagnosed index case of crusted scabies. - Harrison's Principles 22E; Dermatology 2-Volume Set 5e; Fitzpatrick's Dermatology

Diagnosis

The diagnosis of scabies is primarily clinical, resting on three pillars: characteristic pruritus (especially nocturnal), physical findings in typical distributions, and an epidemiologic history of close contact with an infested person. The complete diagnostic triad in cases lacking microscopic confirmation is: pruritus + physical examination findings (burrows, genital lesions) + epidemiologic link. Response to treatment also serves as a diagnostic criterion.

Definitive confirmation requires demonstration of the mite, its eggs, or fecal pellets (scybala) by one of the following methods:

Mineral oil skin scraping: A scalpel or curette is used to scrape infested skin (particularly from burrows); the material is placed in mineral oil and examined under light microscopy. This is the classical gold standard technique.
Transparent adhesive tape test: Tape applied to infested skin and lifted off, then examined microscopically.
Dermoscopy (epiluminescence microscopy): Allows direct in vivo visualization of the mite and eggs. The triangular brown-black structure at the front end of a burrow - known as the "jet with contrail" or "delta-wing sign" - is a dermoscopic hallmark of scabies.
Confocal reflectance microscopy: A non-invasive, high-resolution option with emerging diagnostic utility.
Skin biopsy: Confirms diagnosis only if the section happens to contain a mite or eggs; sensitivity is low.

Per the 2020 International Alliance for the Control of Scabies (IACS) consensus criteria, a confirmed diagnosis requires visualization of mites, eggs, or feces either by light microscopy of skin samples or by a high-powered imaging device or dermoscopy. - Dermatology 2-Volume Set 5e

Differential Diagnosis

Given the intense pruritus and variable morphology of scabies, the differential diagnosis is broad. Key conditions to consider include:

Atopic dermatitis - chronic, often childhood-onset, associated with personal/family atopic history
Contact dermatitis (allergic or irritant) - exposure history, localized distribution
Pityriasis rosea - herald patch, Christmas-tree distribution on trunk, symmetric maculopapular rash
Papular urticaria - urticarial papules following arthropod bites
Secondary syphilis - symmetric maculopapular rash including palms and soles, positive serology
Dermatitis herpetiformis - intensely pruritic vesicles on extensor surfaces, associated with celiac disease
Lichen planus - pruritic, violaceous, polygonal (Wickham's striae) lesions on extremities
Psoriasis - erythematous plaques with silver-white scale (resembles crusted scabies particularly)
Bullous pemphigoid - scabies can both mimic and actually trigger bullous pemphigoid
Folliculitis - perifollicular pustules
In infants: incontinentia pigmenti, acropustulosis of infancy (which can both mimic and follow scabies)
Dermatology 2-Volume Set 5e; Rosen's Emergency Medicine

Complications

The most clinically significant complications of scabies arise from secondary bacterial superinfection:

Impetiginization with Staphylococcus aureus or Streptococcus pyogenes is common, driven by the skin barrier disruption from intense scratching.
Post-streptococcal glomerulonephritis can result from S. pyogenes-induced pyodermas in scabies - this is a recognized cause of kidney disease in endemic communities.
Lymphangitis and septicemia have been reported in crusted scabies due to the sheer density of mites and the massive breach of skin integrity.
Bullous pemphigoid can be triggered by scabies infestation through a mechanism of immune dysregulation.

These infectious complications, particularly post-streptococcal glomerulonephritis in children in tropical regions, represent a major component of the broader disease burden attributable to scabies beyond the infestation itself. - Fitzpatrick's Dermatology

Treatment

Principles of Management

All household members and close contacts must be treated simultaneously, regardless of whether they are symptomatic. This is non-negotiable, because asymptomatic carriers are common and re-infestation from an untreated contact will lead to treatment failure. Treatment should be administered twice - once on day 1 and again on day 8 (one week later) - to kill any larvae that hatched after the first application. Clothing, bedding, and towels used within 72 hours of treatment should be machine-washed in hot water and dried on a high-heat cycle.

First-Line Treatment

Permethrin 5% cream is the first-line agent for classic scabies. It is a synthetic pyrethroid that acts by disrupting sodium channel function in the mite's nerve cell membranes, causing paralysis and death. Application technique is critical:

Apply from the neck down (or from the scalp down in infants, young children, and the elderly) to cover all body surfaces
Particular attention to interdigital spaces, the navel, under the nails, areolae, and genitalia
Applied preferably at bedtime, left on for 8-12 hours, then washed off
Repeated at day 8
Considered safe in pregnancy and is FDA-approved for infants ≥2 months of age
Some early signals of tolerance development have been noted in endemic communities

Systemic Treatment

Oral ivermectin is the key systemic option, particularly for:

Mass drug administration in endemic communities
Crusted scabies (where topical therapy alone is inadequate)
Immunocompromised individuals
When compliance with topical therapy is poor
Institutional outbreaks

Ivermectin is a macrocyclic lactone that enhances glutamate-gated chloride channel activity in invertebrates, causing paralysis and death of the mite. It is given as two oral doses (approximately 200 mcg/kg each), spaced two weeks apart. For heavily infested or immunocompromised patients, additional doses may be required. Though widely used and effective, ivermectin remains off-label for scabies in some jurisdictions. Concerns about developing in vitro tolerance have been raised in scabies-endemic communities. - Fitzpatrick's Dermatology; Harrison's Principles 22E

Other Approved Scabicides

The FDA has approved four topical scabicides:

Agent	Application	Notes
Permethrin 5% cream	Overnight (8-12h), days 1 & 8	First-line; safe in pregnancy; FDA-approved ≥2 months
Crotamiton 10%	Applied on two consecutive days	Lower efficacy than permethrin; also anti-pruritic
Spinosad 0.9% suspension	≥6 hours on day 1	FDA-approved; skin irritation possible
Lindane 1%	Historically used	Neurotoxic; contraindicated in infants, children, pregnant women, and those with seizure disorders; not recommended as first-line

Treatment of Crusted Scabies

Crusted scabies requires aggressive combination therapy:

Oral ivermectin (multiple doses) combined with topical permethrin
Keratolytic agents (e.g., 5-10% salicylic acid) to reduce the hyperkeratotic crust and improve topical agent penetration
Environmental decontamination is essential given the extreme mite burden in the environment
All close contacts and healthcare personnel must be treated simultaneously
Isolation precautions in the institutional setting

Post-Scabetic Itch

A common source of confusion is the persistence of pruritus for 2-4 weeks after successful treatment - the so-called "post-scabetic itch." This is a hypersensitivity reaction to dead mite antigens and does not indicate treatment failure. Topical corticosteroids and oral antihistamines can provide symptomatic relief. Patients should be reassured and not retreated prematurely.

Prevention and Control

Scabies control at the community or institutional level requires a coordinated approach. Key measures include:

Contact tracing and simultaneous treatment of all household and close contacts
Environmental decontamination: washing all clothing, bedding, and towels in hot water; sealing items that cannot be washed in plastic bags for at least 72 hours (the maximum off-host survival time of the mite)
Mass drug administration (MDA) with oral ivermectin has been evaluated in endemic island and Aboriginal communities with promising results in reducing community-wide prevalence
Institutional protocols: prompt identification and isolation of crusted scabies cases; treatment of all healthcare workers with skin contact exposure

In settings where crusted scabies cases are diagnosed in institutional care, information on environmental disinfection is available from the CDC scabies guidelines. - Red Book 2021; Dermatology 2-Volume Set 5e

Summary

Scabies is a globally prevalent, ectoparasitic infestation by Sarcoptes scabiei var. hominis with a 30-day epidermal life cycle. Its clinical hallmark is intense nocturnal pruritus with burrows in characteristic distributions, driven by type IV hypersensitivity to mite antigens after a 4-6 week sensitization period. Crusted scabies represents a hyperinfestation variant in immunocompromised or neurologically impaired hosts that carries enormous epidemiologic risk. Diagnosis is primarily clinical, confirmed by microscopy or dermoscopy. Permethrin 5% cream remains the topical first-line agent; oral ivermectin is increasingly pivotal for systemic disease, mass treatment, and crusted scabies. Simultaneous treatment of all close contacts and environmental decontamination are as important as the choice of scabicide itself.

Sources:

Fitzpatrick's Dermatology, 9th Edition (Chapter 178)
Dermatology 2-Volume Set, 5th Edition (Chapter 84)
Harrison's Principles of Internal Medicine, 22nd Edition (2025)
Rosen's Emergency Medicine: Concepts and Clinical Practice
Red Book 2021: Report of the Committee on Infectious Diseases
Goldman-Cecil Medicine, International Edition

Vsd new recent advances

Reading File

Finding Sources

Searching PubMed

"ventricular septal defect" AND advances

Searching the Web

ventricular septal defect VSD recent advances 2024 2025 transcatheter closure device

Reading File

Searching PubMed

"ventricular septal defect" AND "transcatheter closure"

Reading File

Reading Article

PMID: 37974558

Reading Article

PMID: 38974713

Reading Article

PMID: 41780663

Reading File

Searching PubMed

"ventricular septal defect" AND ("KONAR" OR "biodegradable occluder" OR "3D printing")

Searching PubMed

"ventricular septal defect" AND ("gene therapy" OR "stem cell" OR "fetal intervention")

Reading Article

PMID: 40275637

Reading Article

PMID: 37179234

Finding Sources

I now have comprehensive material from multiple textbooks and recent high-quality PubMed evidence. Let me compile the full PG-level essay on VSD with recent advances.

Ventricular Septal Defect (VSD): A Comprehensive Review with Recent Advances

Introduction

Ventricular septal defect (VSD) is an opening in the interventricular septum that allows communication between the left ventricle (LV) and right ventricle (RV). It is the most common congenital heart defect (CHD), comprising 20-40% of all congenital cardiac lesions. Despite its high prevalence, significant evolution has occurred in its understanding, classification, diagnosis, and management - particularly with the rise of transcatheter closure techniques, novel occluder devices, and emerging biodegradable technologies. - Schwartz's Principles of Surgery 11e; MedComm 2024 [PMID: 38974713]

Classification and Anatomy

VSDs are classified into four anatomical types based on their location within the interventricular septum:

1. Perimembranous (Paramembranous / Conoventricular) VSD

The most common type requiring surgical intervention, comprising approximately 80% of cases. These defects involve the membranous portion of the septum and extend into one or more adjacent components. They may include the malalignment defects seen in tetralogy of Fallot. In rare instances, adhesion of the anterior and septal leaflets of the tricuspid valve to the defect edge creates a channel between the LV and right atrium, producing an exceptionally large left-to-right shunt. Perimembranous VSDs are the most clinically challenging for transcatheter closure because of their proximity to the His bundle and the atrioventricular node, creating risk of complete heart block.

2. Muscular VSD

The most common type overall, muscular VSDs are entirely surrounded by muscle and can occur anywhere along the trabecular septum: anterior, midventricular, posterior, or apical positions. The rare "Swiss-cheese" variant consists of multiple communications between the ventricles, significantly complicating repair.

3. AV Canal (Inlet) VSD

Inlet defects occur when part or all of the AV canal septum is absent. The defect lies beneath the tricuspid valve and is bounded upstream by the tricuspid annulus with no intervening muscle. These are commonly associated with Down syndrome as part of complete atrioventricular septal defect.

4. Supracristal (Outlet / Conal) VSD

These result from a defect within the conal (outlet) septum, limited upstream by the pulmonary valve and otherwise surrounded by infundibular muscle. They are at risk for progressive aortic valve prolapse and regurgitation due to lack of support for the right coronary cusp. - Schwartz's Principles of Surgery 11e

VSDs vary in size from 3-4 mm to more than 3 cm. A key physiological distinction is between restrictive VSDs (small; high resistance to flow; RV pressure normal or minimally elevated; Qp:Qs rarely >1.5:1) and non-restrictive VSDs (large; equalize ventricular pressures; massive left-to-right shunting; rapidly causes pulmonary overcirculation and CHF).

Pathophysiology

The direction and magnitude of shunting across a VSD is determined by the size of the defect and the ratio of pulmonary vascular resistance (PVR) to systemic vascular resistance (SVR). In a small restrictive VSD, the defect itself limits flow - RV pressure remains near normal and shunting is modest. In a large non-restrictive VSD, LV and RV pressures equalize, and the Qp:Qs ratio is determined purely by the PVR:SVR ratio.

If a large VSD is left untreated, chronic volume and pressure overload of the pulmonary vasculature triggers progressive pulmonary vascular remodeling: intimal proliferation, medial hypertrophy, and eventually irreversible obliterative arteriopathy. This process leads to rising PVR, which eventually surpasses SVR, reversing the shunt direction to right-to-left - the condition known as Eisenmenger syndrome. At this stage the patient becomes inoperable and develops progressive cyanosis, polycythemia, and eventually right heart failure. Paul Wood first coined the term "Eisenmenger complex" in 1958 to describe pulmonary hypertension with reversed central shunt. - Murray & Nadel's Textbook of Respiratory Medicine

Clinical Features

Symptoms

Small VSDs: Usually asymptomatic. The characteristic finding is a loud, harsh, holosystolic murmur at the left sternal border. Long-term risk of infective endocarditis (IE) is present due to endocardial damage from the high-velocity jet.
Moderate-to-large VSDs: Congestive heart failure in infancy - poor feeding, failure to thrive, recurrent respiratory infections, tachypnea, and diaphoresis with feeds.
Eisenmenger syndrome: Progressive cyanosis, clubbing, polycythemia, right heart failure - at this stage VSD closure is contraindicated.

Physical Examination

Holosystolic murmur (best heard at left sternal border, 3rd-4th intercostal space) - note that with Eisenmenger, the murmur paradoxically softens or disappears as shunting equalizes
Right ventricular heave with large VSDs
Loud P2 if pulmonary hypertension has developed
Signs of CHF: hepatomegaly, tachycardia, gallop rhythm

Diagnosis

Electrocardiography

Small VSD: Normal ECG
Moderate-large VSD: Left ventricular hypertrophy (LVH) or biventricular hypertrophy
Established Eisenmenger: Right ventricular hypertrophy (RVH) and right axis deviation

Chest X-Ray

Cardiomegaly and pulmonary plethora (increased pulmonary vascular markings) in large VSDs
Eisenmenger: Prominent main and proximal pulmonary arteries with peripheral pruning

Echocardiography

Echocardiography is the cornerstone of VSD diagnosis. 2D and Doppler echocardiography provides definitive diagnosis, accurately classifies the defect type, estimates shunt magnitude (Qp:Qs), quantifies LV volume overload, and estimates pulmonary arterial pressures via tricuspid regurgitation jet velocity. Cardiac catheterization has largely been supplanted by echocardiography except in older children and adults where precise measurement of pulmonary vascular resistance is required before recommending closure. - Schwartz's Principles of Surgery 11e

3D Echocardiography and Cardiac MRI

Three-dimensional echocardiography now provides superior morphological delineation of defect geometry, particularly for complex or multiple VSDs, guiding both surgical and transcatheter approaches. Cardiac MRI allows quantification of Qp:Qs with high accuracy without ionizing radiation and is increasingly used in adolescents and adults.

Spontaneous Closure

A crucial clinical principle: VSDs may close spontaneously. The probability of spontaneous closure is inversely related to age - infants at 1 month of age have an 80% incidence of spontaneous closure, whereas by 12 months this falls to only 25%. This fundamentally shapes decision-making; a small or moderate VSD may be observed for a period of time in an asymptomatic infant before surgical or catheter intervention is recommended. Muscular VSDs have the highest rate of spontaneous closure. Perimembranous VSDs may also close through aneurysm formation of the membranous septum or by adherence of tricuspid valve tissue. - Schwartz's Principles of Surgery 11e

Indications for Closure

Current indications for VSD closure include:

Symptomatic VSD (CHF, failure to thrive) at any age
Asymptomatic VSD with Qp:Qs ≥ 2:1 with LV volume overload
VSD with progressive aortic valve regurgitation (particularly supracristal type)
History of infective endocarditis
Prior to other cardiac surgery when VSD is hemodynamically significant

Contraindications: Established Eisenmenger syndrome (irreversible pulmonary vascular disease with PVR > 8-10 Wood units and Qp:Qs < 1.5:1) is an absolute contraindication to closure.

Treatment

1. Medical Management

There is no medical therapy that "treats" a VSD. Medical management is supportive - management of CHF with diuretics (furosemide), ACE inhibitors, and nutritional support while awaiting spontaneous closure or as a bridge to surgical/catheter repair.

2. Surgical Repair (Gold Standard)

Open surgical repair under cardiopulmonary bypass (CPB) with cardioplegic arrest remains the definitive and gold standard treatment. Techniques include:

Patch closure: A synthetic patch (Dacron/Gore-Tex) or autologous pericardium is sutured over the defect. This is the most common technique.
Primary suture closure: Feasible only for small muscular defects.
Right atrial approach: The preferred initial approach for most VSDs, allowing inspection of anatomy without ventriculotomy and avoiding RV dysfunction.
Right ventriculotomy: Reserved for anterior muscular and some apical defects where atrial exposure is inadequate.
Pulmonary arteriotomy approach: Used for supracristal defects.

Intraoperative transesophageal echocardiography (TEE) is routine to assess for residual defects immediately after repair. Results are excellent - hospital mortality is near 0% in isolated VSD even in very small infants. The main risk factor for mortality remains the presence of associated cardiac lesions in symptomatic neonates. - Schwartz's Principles of Surgery 11e

For the "Swiss-cheese" septum, when definitive repair is not possible in infancy, pulmonary artery banding (PAB) is employed as a palliative measure to control pulmonary blood flow, allowing time for spontaneous closure of smaller defects and deferring complex repair to a later age.

3. Transcatheter (Percutaneous) Device Closure

Transcatheter closure has emerged as a major advance in VSD management, particularly for muscular and selected perimembranous defects. Its advantages include avoidance of CPB and sternotomy, shorter hospital stay, faster recovery, and lower risk of CPB-related complications.

Recent Advances

A. Novel Transcatheter Devices

KONAR-MF (LifeTech Multifunctional Occluder)

The KONAR-MF occluder (LifeTech Scientific) represents the most significant recent device advance in transcatheter VSD closure. Approved by the CE (European Conformity) in 2018, it was specifically engineered to minimize damage to adjacent structures - particularly the aortic and tricuspid valves - and to reduce rhythm complications compared to earlier devices.

A 2025 systematic review and meta-analysis (Kabadayi et al., Catheterization and Cardiovascular Interventions [PMID: 40275637]) analyzing 19 studies comprising 839 patients reported:

Device implementation success rate: 94.2% (95% CI: 90.1-96.5)
Complete atrioventricular block on follow-up: 2.3% (notably lower than historical rates with conventional Amplatzer-type devices)
New-onset aortic regurgitation: 4.4%
New-onset tricuspid regurgitation: 3.7%
Device embolization: 4.1%

The IACS consensus criteria and multiple multicenter studies including from India (Koneti et al., Pediatric Cardiology 2025 [PMID: 38689022]) have validated the KONAR-MF's safety profile across all age groups. Machine learning models have also been applied to predict post-procedural arrhythmia risk after KONAR-MF closure, aiding pre-procedural patient selection (Yan et al., Kardiologia Polska 2025).

Amplatzer Duct Occluder II (ADO II)

The ADO II (Abbott) has been increasingly used off-label for small perimembranous and muscular VSDs, especially in infants under 10 kg, with good results and a low arrhythmia profile when used in this context.

B. Fully Biodegradable (Bioabsorbable) Occluders

One of the most transformative emerging technologies is the development of fully bioabsorbable cardiac occluders. Long-term follow-up data on conventional nitinol (Nitinol wire mesh Amplatzer-type) devices have revealed late complications including hemolysis, thrombus formation, metal allergy, cardiac erosion, and sustained complete atrioventricular block - all attributed to the permanent metallic skeleton.

A landmark multicenter RCT (Wang et al., Science Bulletin 2023 [PMID: 37179234]) randomized 108 patients with perimembranous VSD >3 mm to either a novel fully biodegradable occluder vs. conventional nitinol occluder with 24-month follow-up. Key findings:

All 108 patients were successfully implanted and completed the trial
No residual shunt >2 mm was observed during follow-up in either group
Transthoracic echocardiography showed the bioabsorbable occluder image decreased primarily during the first year and completely disappeared within 24 months - confirming full biodegradation
Sustained conduction block was significantly lower in the bioabsorbable group: 0/54 vs. 6/54 (P = 0.036) at 24-month follow-up
Overall arrhythmia incidence: 5.56% (bioabsorbable) vs. 14.81% (nitinol), though not statistically significant (P = 0.112)
Conclusion: The fully biodegradable occluder is non-inferior in efficacy and safety to nitinol, with significantly lower sustained conduction block.

Materials under active research include polydioxanone (PDO) and poly(lactic-co-glycolic acid) (PLGA)-based scaffolds that degrade completely over 12-24 months, leaving no residual metallic foreign body. - J Biomed Mater Res B, 2024 [PMID: 37974558]; Bioact Mater, 2023 [PMID: 36632501]

C. Post-Myocardial Infarction VSD: Evolving Management

Post-MI ventricular septal defect (post-MI VSD / ventricular septal rupture) is a life-threatening mechanical complication of acute MI with a reported incidence of approximately 0.3% and very high early mortality. It represents a distinct entity from congenital VSD.

A 2026 review (Castiglione et al., American Journal of Cardiology [PMID: 41780663]) summarizes the current state of management:

Timing: Delayed surgery (>7 days) in hemodynamically stable patients is associated with improved outcomes compared to emergency surgery, as fibrosis around the defect edges improves repair durability. However, in patients with refractory cardiogenic shock, urgent intervention is required.

Surgical techniques (gold standard for post-MI VSD):

Daggett technique: Trans-infarct approach with patch closure
David technique: Endocardial closure
Double-patch infarct exclusion (most widely adopted): Endocardial patch repair that excludes the infarcted area and the VSD from the LV cavity

Percutaneous (transcatheter) closure: Used as definitive therapy in high-risk patients unable to tolerate surgery, or as a bridge to surgery by reducing the shunt fraction and improving hemodynamics before definitive repair. Residual shunts are more common with percutaneous closure than with surgery. A meta-analysis (Aramin et al., Annals of Medicine and Surgery, 2024 [PMID: 39239065]) directly compared surgical vs. transcatheter closure for post-infarction VSD.

Mechanical Circulatory Support (MCS): A major recent advance in post-MI VSD management is aggressive pre- and peri-operative MCS:

Intra-aortic balloon pump (IABP): Reduces LV afterload and shunt fraction
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO): Provides full cardiorespiratory support in refractory shock
Impella (axial flow pump): Unloads the LV directly, reduces shunting, and allows "myocardial recovery" before repair

Hybrid approaches (combining surgical and transcatheter techniques in the same session) and beating-heart surgical techniques (avoiding arrest) have also shown promise in selected cases.

D. Advances in Imaging and Planning

Intracardiac echocardiography (ICE): Increasingly used to guide transcatheter VSD closure in real time, reducing radiation and contrast exposure, and eliminating the need for general anesthesia in older patients.

3D Printing and Patient-Specific Modeling: 3D-printed cardiac models derived from CT and MRI data are being used for pre-procedural planning of complex VSD repairs and device selection, particularly for muscular and post-MI VSDs with complex geometry.

Fusion imaging (real-time fusion of fluoroscopy with 3D echocardiography) provides enhanced guidance for device deployment and reduces procedural complications.

E. Pulmonary Vasodilator Therapy in Eisenmenger Syndrome

While not a "closure" advance, a significant development in the management of VSD-related Eisenmenger syndrome has been the application of targeted pulmonary arterial hypertension (PAH) therapies - endothelin receptor antagonists (bosentan, ambrisentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil), and prostacyclin analogues (iloprost, treprostinil). These agents improve functional capacity, exercise tolerance, and hemodynamics in Eisenmenger patients who are not candidates for closure. In selected patients with borderline operability, PAH therapy is being investigated as a "treat-and-repair" strategy to reduce PVR enough to enable safe closure.

F. Perventricular (Hybrid) Closure

The perventricular approach represents a hybrid between surgical and catheter-based techniques. Under direct surgical visualization through a limited sternotomy (but without CPB), a device is deployed transventricularly using a delivery sheath advanced through a small purse-string incision in the RV free wall under TEE guidance. This is particularly valuable for:

Muscular VSDs in small infants where full percutaneous access is limited by patient size
Multiple "Swiss-cheese" VSDs
Infants with poor vascular access

Summary Table: Traditional vs. Recent Advances

Domain	Traditional	Recent Advances (2023-2026)
Transcatheter device	Amplatzer Muscular VSD Occluder	KONAR-MF (CE 2018) - lower heart block, less valve injury
Occluder material	Nitinol (permanent metal)	Fully biodegradable (PLGA/PDO) - disappears in 24 months
Post-MI VSD management	Emergency surgery alone	Staged repair + VA-ECMO/Impella bridge; percutaneous closure
Imaging guidance	Fluoroscopy + TEE	ICE, 3D echo fusion, CT-derived 3D printing
Inoperable Eisenmenger	Supportive care	Targeted PAH therapy (bosentan, sildenafil, treprostinil)
Complex infant VSD	PA band then surgery	Perventricular hybrid closure without CPB

Conclusion

VSD management has shifted from an era of purely open surgical repair toward a nuanced, individualized, and increasingly minimally invasive paradigm. The KONAR-MF occluder has meaningfully reduced the risk of conduction block and valve injury in transcatheter perimembranous VSD closure. Fully bioabsorbable occluders have demonstrated non-inferiority to nitinol devices in an RCT with the critical advantage of no permanent metallic implant and significantly lower sustained heart block. In post-MI VSD, advanced MCS strategies and staged percutaneous approaches are expanding therapeutic options beyond emergency surgery. Imaging advances - ICE, 3D echo fusion, and 3D printing - are making complex VSD interventions safer and more precise. The field continues to evolve rapidly, with ongoing studies needed to define optimal device selection, timing, and long-term outcomes for each VSD subtype.

Sources:

Schwartz's Principles of Surgery, 11th Edition (Chapter 20)
Sabiston Textbook of Surgery
Harrison's Principles of Internal Medicine, 22E (2025)
Murray & Nadel's Textbook of Respiratory Medicine
Kabadayi et al., Catheter Cardiovasc Interv 2025 [PMID: 40275637] - KONAR-MF Systematic Review & Meta-Analysis
Wang et al., Science Bulletin 2023 [PMID: 37179234] - Biodegradable Occluder RCT
Castiglione et al., Am J Cardiol 2026 [PMID: 41780663] - Post-MI VSD Management Review
Xu et al., J Biomed Mater Res B 2024 [PMID: 37974558] - Biodegradable Polymer Occluders Review
Meng et al., MedComm 2024 [PMID: 38974713] - CHD Pathophysiology & Treatment Review

This is a shared conversation. Sign in to Orris to start your own chat.